Titre : Benzazépines

Benzazépines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Myopia

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dépendance aux benzazépines ?

Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs.
Dépendance aux médicaments Benzodiazépines
#2

Quels tests sont utilisés pour évaluer l'usage des benzazépines ?

Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés.
Tests de dépistage Benzodiazépines
#3

Quels critères DSM sont liés aux benzazépines ?

Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines.
Trouble d'usage de substances Benzodiazépines
#4

Comment évaluer les effets secondaires des benzazépines ?

L'évaluation se fait par l'observation des symptômes et l'historique médical du patient.
Effets secondaires Benzodiazépines
#5

Quels signes indiquent une surdose de benzazépines ?

Les signes incluent confusion, somnolence excessive, et dépression respiratoire.
Surdose Benzodiazépines

Symptômes 5

#1

Quels sont les symptômes d'une surconsommation de benzazépines ?

Les symptômes incluent somnolence, confusion, et troubles de la coordination.
Symptômes Benzodiazépines
#2

Comment se manifeste le sevrage des benzazépines ?

Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions.
Sevrage Benzodiazépines
#3

Quels effets à long terme des benzazépines ?

Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance.
Effets à long terme Benzodiazépines
#4

Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?

Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil.
Anxiété Benzodiazépines
#5

Les benzazépines causent-elles des troubles de la mémoire ?

Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose.
Troubles de la mémoire Benzodiazépines

Prévention 5

#1

Comment prévenir la dépendance aux benzazépines ?

Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives.
Prévention Dépendance aux médicaments
#2

Quelles sont les recommandations pour l'utilisation des benzazépines ?

Utiliser à la dose minimale efficace et pour la durée la plus courte possible.
Recommandations Benzodiazépines
#3

Comment éduquer les patients sur les benzazépines ?

Informer sur les risques, les effets secondaires et l'importance du suivi médical.
Éducation des patients Benzodiazépines
#4

Quels sont les risques d'auto-médication avec des benzazépines ?

L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses.
Auto-médication Benzodiazépines
#5

Comment réduire l'usage des benzazépines dans la population ?

Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés.
Réduction de l'usage Benzodiazépines

Traitements 5

#1

Comment sont prescrites les benzazépines ?

Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines.
Prescription Benzodiazépines
#2

Quelles alternatives aux benzazépines pour l'anxiété ?

Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives.
Antidépresseurs Anxiété
#3

Comment gérer une overdose de benzazépines ?

L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil.
Overdose Benzodiazépines
#4

Les benzazépines sont-elles efficaces pour l'insomnie ?

Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires.
Insomnie Benzodiazépines
#5

Quel suivi est nécessaire lors de l'utilisation de benzazépines ?

Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires.
Suivi médical Benzodiazépines

Complications 5

#1

Quelles complications peuvent survenir avec les benzazépines ?

Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence.
Complications Benzodiazépines
#2

Les benzazépines augmentent-elles le risque de chutes ?

Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées.
Chutes Benzodiazépines
#3

Comment les benzazépines affectent-elles la respiration ?

Elles peuvent déprimer le système respiratoire, surtout en cas de surdose.
Dépression respiratoire Benzodiazépines
#4

Les benzazépines peuvent-elles interagir avec d'autres médicaments ?

Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs.
Interactions médicamenteuses Benzodiazépines
#5

Quels sont les effets des benzazépines sur la grossesse ?

Elles peuvent causer des malformations congénitales et des complications néonatales.
Grossesse Benzodiazépines

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de dépendance aux benzazépines ?

Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque.
Dépendance Benzodiazépines
#2

Les personnes âgées sont-elles plus à risque avec les benzazépines ?

Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes.
Personnes âgées Benzodiazépines
#3

Comment l'usage prolongé de benzazépines affecte-t-il le risque ?

L'usage prolongé augmente le risque de dépendance et de troubles cognitifs.
Usage prolongé Benzodiazépines
#4

Quels facteurs psychologiques influencent l'usage des benzazépines ?

L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines.
Facteurs psychologiques Benzodiazépines
#5

Les interactions médicamenteuses augmentent-elles les risques ?

Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents.
Interactions médicamenteuses Benzodiazépines
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzazépines : Questions médicales les plus fréquentes", "headline": "Benzazépines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzazépines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzazépines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés hétérobicycliques", "url": "https://questionsmedicales.fr/mesh/D006574", "about": { "@type": "MedicalCondition", "name": "Composés hétérobicycliques", "code": { "@type": "MedicalCode", "code": "D006574", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Benzodiazépines", "alternateName": "Benzodiazepines", "url": "https://questionsmedicales.fr/mesh/D001569", "about": { "@type": "MedicalCondition", "name": "Benzodiazépines", "code": { "@type": "MedicalCode", "code": "D001569", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alprazolam", "alternateName": "Alprazolam", "url": "https://questionsmedicales.fr/mesh/D000525", "about": { "@type": "MedicalCondition", "name": "Alprazolam", "code": { "@type": "MedicalCode", "code": "D000525", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.030" } } }, { "@type": "MedicalWebPage", "name": "Benzodiazépinones", "alternateName": "Benzodiazepinones", "url": "https://questionsmedicales.fr/mesh/D001570", "about": { "@type": "MedicalCondition", "name": "Benzodiazépinones", "code": { "@type": "MedicalCode", "code": "D001570", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } } ] }, { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } }, { "@type": "MedicalWebPage", "name": "Chlordiazépoxyde", "alternateName": "Chlordiazepoxide", "url": "https://questionsmedicales.fr/mesh/D002707", "about": { "@type": "MedicalCondition", "name": "Chlordiazépoxyde", "code": { "@type": "MedicalCode", "code": "D002707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.150" } } }, { "@type": "MedicalWebPage", "name": "Clobazam", "alternateName": "Clobazam", "url": "https://questionsmedicales.fr/mesh/D000078306", "about": { "@type": "MedicalCondition", "name": "Clobazam", "code": { "@type": "MedicalCode", "code": "D000078306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.165" } } }, { "@type": "MedicalWebPage", "name": "Clorazépate dipotassique", "alternateName": "Clorazepate Dipotassium", "url": "https://questionsmedicales.fr/mesh/D003009", "about": { "@type": "MedicalCondition", "name": "Clorazépate dipotassique", "code": { "@type": "MedicalCode", "code": "D003009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.180" } } }, { "@type": "MedicalWebPage", "name": "Estazolam", "alternateName": "Estazolam", "url": "https://questionsmedicales.fr/mesh/D004949", "about": { "@type": "MedicalCondition", "name": "Estazolam", "code": { "@type": "MedicalCode", "code": "D004949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.250" } } }, { "@type": "MedicalWebPage", "name": "Médazépam", "alternateName": "Medazepam", "url": "https://questionsmedicales.fr/mesh/D008472", "about": { "@type": "MedicalCondition", "name": "Médazépam", "code": { "@type": "MedicalCode", "code": "D008472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.550" } } }, { "@type": "MedicalWebPage", "name": "Midazolam", "alternateName": "Midazolam", "url": "https://questionsmedicales.fr/mesh/D008874", "about": { "@type": "MedicalCondition", "name": "Midazolam", "code": { "@type": "MedicalCode", "code": "D008874", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.575" } } }, { "@type": "MedicalWebPage", "name": "Olanzapine", "alternateName": "Olanzapine", "url": "https://questionsmedicales.fr/mesh/D000077152", "about": { "@type": "MedicalCondition", "name": "Olanzapine", "code": { "@type": "MedicalCode", "code": "D000077152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.738" } } }, { "@type": "MedicalWebPage", "name": "Triazolam", "alternateName": "Triazolam", "url": "https://questionsmedicales.fr/mesh/D014229", "about": { "@type": "MedicalCondition", "name": "Triazolam", "code": { "@type": "MedicalCode", "code": "D014229", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Diltiazem", "alternateName": "Diltiazem", "url": "https://questionsmedicales.fr/mesh/D004110", "about": { "@type": "MedicalCondition", "name": "Diltiazem", "code": { "@type": "MedicalCode", "code": "D004110", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.150" } } }, { "@type": "MedicalWebPage", "name": "Fénoldopam", "alternateName": "Fenoldopam", "url": "https://questionsmedicales.fr/mesh/D018818", "about": { "@type": "MedicalCondition", "name": "Fénoldopam", "code": { "@type": "MedicalCode", "code": "D018818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.300" } } }, { "@type": "MedicalWebPage", "name": "Galantamine", "alternateName": "Galantamine", "url": "https://questionsmedicales.fr/mesh/D005702", "about": { "@type": "MedicalCondition", "name": "Galantamine", "code": { "@type": "MedicalCode", "code": "D005702", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.525" } } }, { "@type": "MedicalWebPage", "name": "Ivabradine", "alternateName": "Ivabradine", "url": "https://questionsmedicales.fr/mesh/D000077550", "about": { "@type": "MedicalCondition", "name": "Ivabradine", "code": { "@type": "MedicalCode", "code": "D000077550", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.801" } } }, { "@type": "MedicalWebPage", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "alternateName": "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine", "url": "https://questionsmedicales.fr/mesh/D015647", "about": { "@type": "MedicalCondition", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "code": { "@type": "MedicalCode", "code": "D015647", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.838" } } }, { "@type": "MedicalWebPage", "name": "Tolvaptan", "alternateName": "Tolvaptan", "url": "https://questionsmedicales.fr/mesh/D000077602", "about": { "@type": "MedicalCondition", "name": "Tolvaptan", "code": { "@type": "MedicalCode", "code": "D000077602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzazépines", "alternateName": "Benzazepines", "code": { "@type": "MedicalCode", "code": "D001552", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Bernhard Wünsch", "url": "https://questionsmedicales.fr/author/Bernhard%20W%C3%BCnsch", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany." } }, { "@type": "Person", "name": "Dirk Schepmann", "url": "https://questionsmedicales.fr/author/Dirk%20Schepmann", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany." } }, { "@type": "Person", "name": "Simon M Ametamey", "url": "https://questionsmedicales.fr/author/Simon%20M%20Ametamey", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch." } }, { "@type": "Person", "name": "Nadine Ritter", "url": "https://questionsmedicales.fr/author/Nadine%20Ritter", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de." } }, { "@type": "Person", "name": "Guiscard Seebohm", "url": "https://questionsmedicales.fr/author/Guiscard%20Seebohm", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Epidemiology of Myopia: Prevalence, Risk Factors and Effects of Myopia.", "datePublished": "2024-10-09", "url": "https://questionsmedicales.fr/article/39384213", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/a-2340-1790" } }, { "@type": "ScholarlyArticle", "name": "Evaluation of myopia-associated genes in a Han Chinese population with high myopia.", "datePublished": "2023-05-11", "url": "https://questionsmedicales.fr/article/37165999", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/13816810.2023.2191709" } }, { "@type": "ScholarlyArticle", "name": "Extreme myopia is more susceptible to SOX2 gene than high myopia.", "datePublished": "2023-03-14", "url": "https://questionsmedicales.fr/article/36921835", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.exer.2023.109435" } }, { "@type": "ScholarlyArticle", "name": "Prevalence of myopia and uncorrected myopia among 721 032 schoolchildren in a city-wide vision screening in southern China: the Shantou Myopia Study.", "datePublished": "2023-11-22", "url": "https://questionsmedicales.fr/article/36198476", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bjo-2021-320940" } }, { "@type": "ScholarlyArticle", "name": "EVO/EVO+ Visian Implantable Collamer Lenses for the correction of myopia and myopia with astigmatism.", "datePublished": "2023-02-10", "url": "https://questionsmedicales.fr/article/36708714", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/17434440.2023.2174429" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzazépines", "item": "https://questionsmedicales.fr/mesh/D001552" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzazépines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzazépines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzazépines", "description": "Comment diagnostiquer une dépendance aux benzazépines ?\nQuels tests sont utilisés pour évaluer l'usage des benzazépines ?\nQuels critères DSM sont liés aux benzazépines ?\nComment évaluer les effets secondaires des benzazépines ?\nQuels signes indiquent une surdose de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Myopia#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzazépines", "description": "Quels sont les symptômes d'une surconsommation de benzazépines ?\nComment se manifeste le sevrage des benzazépines ?\nQuels effets à long terme des benzazépines ?\nQuels symptômes d'anxiété peuvent être soulagés par les benzazépines ?\nLes benzazépines causent-elles des troubles de la mémoire ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Myopia#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzazépines", "description": "Comment prévenir la dépendance aux benzazépines ?\nQuelles sont les recommandations pour l'utilisation des benzazépines ?\nComment éduquer les patients sur les benzazépines ?\nQuels sont les risques d'auto-médication avec des benzazépines ?\nComment réduire l'usage des benzazépines dans la population ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Myopia#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzazépines", "description": "Comment sont prescrites les benzazépines ?\nQuelles alternatives aux benzazépines pour l'anxiété ?\nComment gérer une overdose de benzazépines ?\nLes benzazépines sont-elles efficaces pour l'insomnie ?\nQuel suivi est nécessaire lors de l'utilisation de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Myopia#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzazépines", "description": "Quelles complications peuvent survenir avec les benzazépines ?\nLes benzazépines augmentent-elles le risque de chutes ?\nComment les benzazépines affectent-elles la respiration ?\nLes benzazépines peuvent-elles interagir avec d'autres médicaments ?\nQuels sont les effets des benzazépines sur la grossesse ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Myopia#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzazépines", "description": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?\nLes personnes âgées sont-elles plus à risque avec les benzazépines ?\nComment l'usage prolongé de benzazépines affecte-t-il le risque ?\nQuels facteurs psychologiques influencent l'usage des benzazépines ?\nLes interactions médicamenteuses augmentent-elles les risques ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Myopia#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance aux benzazépines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'usage des benzazépines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels critères DSM sont liés aux benzazépines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des benzazépines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par l'observation des symptômes et l'historique médical du patient." } }, { "@type": "Question", "name": "Quels signes indiquent une surdose de benzazépines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence excessive, et dépression respiratoire." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une surconsommation de benzazépines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent somnolence, confusion, et troubles de la coordination." } }, { "@type": "Question", "name": "Comment se manifeste le sevrage des benzazépines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions." } }, { "@type": "Question", "name": "Quels effets à long terme des benzazépines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance." } }, { "@type": "Question", "name": "Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil." } }, { "@type": "Question", "name": "Les benzazépines causent-elles des troubles de la mémoire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose." } }, { "@type": "Question", "name": "Comment prévenir la dépendance aux benzazépines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives." } }, { "@type": "Question", "name": "Quelles sont les recommandations pour l'utilisation des benzazépines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser à la dose minimale efficace et pour la durée la plus courte possible." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les benzazépines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Informer sur les risques, les effets secondaires et l'importance du suivi médical." } }, { "@type": "Question", "name": "Quels sont les risques d'auto-médication avec des benzazépines ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses." } }, { "@type": "Question", "name": "Comment réduire l'usage des benzazépines dans la population ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés." } }, { "@type": "Question", "name": "Comment sont prescrites les benzazépines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines." } }, { "@type": "Question", "name": "Quelles alternatives aux benzazépines pour l'anxiété ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives." } }, { "@type": "Question", "name": "Comment gérer une overdose de benzazépines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil." } }, { "@type": "Question", "name": "Les benzazépines sont-elles efficaces pour l'insomnie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires." } }, { "@type": "Question", "name": "Quel suivi est nécessaire lors de l'utilisation de benzazépines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les benzazépines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence." } }, { "@type": "Question", "name": "Les benzazépines augmentent-elles le risque de chutes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées." } }, { "@type": "Question", "name": "Comment les benzazépines affectent-elles la respiration ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent déprimer le système respiratoire, surtout en cas de surdose." } }, { "@type": "Question", "name": "Les benzazépines peuvent-elles interagir avec d'autres médicaments ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs." } }, { "@type": "Question", "name": "Quels sont les effets des benzazépines sur la grossesse ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent causer des malformations congénitales et des complications néonatales." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque avec les benzazépines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes." } }, { "@type": "Question", "name": "Comment l'usage prolongé de benzazépines affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé augmente le risque de dépendance et de troubles cognitifs." } }, { "@type": "Question", "name": "Quels facteurs psychologiques influencent l'usage des benzazépines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines." } }, { "@type": "Question", "name": "Les interactions médicamenteuses augmentent-elles les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 09/05/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

31 au total
└─

Benzodiazépines

Benzodiazepines D001569 - D03.633.100.079.080
└─

Diltiazem

Diltiazem D004110 - D03.633.100.079.150
└─

Fénoldopam

Fenoldopam D018818 - D03.633.100.079.300
└─

Galantamine

Galantamine D005702 - D03.633.100.079.525
└─

Ivabradine

Ivabradine D000077550 - D03.633.100.079.801
└─

1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine D015647 - D03.633.100.079.838
└─

Tolvaptan

Tolvaptan D000077602 - D03.633.100.079.875
└─└─

Alprazolam

Alprazolam D000525 - D03.633.100.079.080.030
└─└─

Benzodiazépinones

Benzodiazepinones D001570 - D03.633.100.079.080.070
└─└─

Chlordiazépoxyde

Chlordiazepoxide D002707 - D03.633.100.079.080.150
└─└─

Clobazam

Clobazam D000078306 - D03.633.100.079.080.165
└─└─

Clorazépate dipotassique

Clorazepate Dipotassium D003009 - D03.633.100.079.080.180
└─└─

Estazolam

Estazolam D004949 - D03.633.100.079.080.250
└─└─

Médazépam

Medazepam D008472 - D03.633.100.079.080.550
└─└─

Midazolam

Midazolam D008874 - D03.633.100.079.080.575
└─└─

Olanzapine

Olanzapine D000077152 - D03.633.100.079.080.738
└─└─

Triazolam

Triazolam D014229 - D03.633.100.079.080.900
└─└─└─

Bromazépam

Bromazepam D001960 - D03.633.100.079.080.070.110
└─└─└─

Clonazépam

Clonazepam D002998 - D03.633.100.079.080.070.150
└─└─└─

Dévazépide

Devazepide D020109 - D03.633.100.079.080.070.200
└─└─└─

Diazépam

Diazepam D003975 - D03.633.100.079.080.070.216
└─└─└─

Flumazénil

Flumazenil D005442 - D03.633.100.079.080.070.305
└─└─└─

Flunitrazépam

Flunitrazepam D005445 - D03.633.100.079.080.070.320
└─└─└─

Flurazépam

Flurazepam D005479 - D03.633.100.079.080.070.348
└─└─└─

Lorazépam

Lorazepam D008140 - D03.633.100.079.080.070.450
└─└─└─

Nitrazépam

Nitrazepam D009567 - D03.633.100.079.080.070.565
└─└─└─

Oxazépam

Oxazepam D010076 - D03.633.100.079.080.070.663
└─└─└─

Pirenzépine

Pirenzepine D010890 - D03.633.100.079.080.070.750
└─└─└─

Prazépam

Prazepam D011222 - D03.633.100.079.080.070.784
└─└─└─

Témazépam

Temazepam D013693 - D03.633.100.079.080.070.880
└─└─└─└─

Nordazépam

Nordazepam D003708 - D03.633.100.079.080.070.216.500

Auteurs principaux

Bernhard Wünsch

9 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.

Dirk Schepmann

7 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.

Simon M Ametamey

5 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch.
Publications dans "Benzazépines" :

Nadine Ritter

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.
  • Chembion, University of Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.

Guiscard Seebohm

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.

Alexander Markus

3 publications dans cette catégorie

Affiliations :
  • Institut für Pharmazeutische und Medizinische Chemie der Universität Münster, Münster, Germany.

Paul Disse

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.

Julian A Schreiber

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Nathalie Strutz-Seebohm

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.

Nengneng Zhou

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Fangli Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Lei Wang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Xiang Gao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Xiaowei Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Man Zhang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.

Álvaro Velasco-Rubio

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Jesús A Varela

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Carlos Saá

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.

Yoshikazu Arai

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: arai.yoshikazu.mh@daiichisankyo.co.jp.

Yohei Kiyotsuka

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

Sources (1679 au total)

Evaluation of myopia-associated genes in a Han Chinese population with high myopia.

High myopia is a leading cause of blindness worldwide. However, the exact etiology and mechanism of high myopia remain unclear. Previous genome-wide association study has demonstrated that nine single... Seven SNPs were genotyped by the MassARRAY iPLEX Gold method in a Han Chinese cohort with the majority from Henan region (central China), which included 361 patients with high myopia and 749 healthy c... In terms of genotyped SNPs, the allele frequency of rs698047 locus of the HIVEP3 gene were statistically different between myopia and control groups initially, but the difference disappeared after Bon... There was no demonstrated association between the occurrence of high myopia in the Chinese Han population and polymorphisms in the following loci: HIVEP3 (rs698047), NFASC/CNTN2 (rs2246661), ZC3H11B (...

Extreme myopia is more susceptible to SOX2 gene than high myopia.

To explore the association between two single-nucleotide polymorphisms (SNPs) in the SOX2 gene and high and extreme myopia in the Han Chinese population.... A genetic association study using a case-control method was performed with 139 high myopia, 318 extreme myopia, and 918 healthy participants from the Chinese Han population. Two SNPs (rs4459940 and rs... The mean ages of the extreme myopia and control subjects were 47.44 ± 15.59 and 44.15 ± 14.08 years, respectively. The rs4575941 SNP of the SOX2 gene and the GG and AG genotypes showed no significant ... The SOX2 rs4575941 polymorphism, in Chinese Han population, contributes to the susceptibility of extreme myopia. SOX2 may thus be implicated in extreme myopia rather than in high myopia....

Prevalence of myopia and uncorrected myopia among 721 032 schoolchildren in a city-wide vision screening in southern China: the Shantou Myopia Study.

To explore the prevalence and risk factors for myopia and uncorrected myopia in schoolchildren in southern China.... The government-led Shantou Myopia Study was conducted from September 2020 to June 2021. Non-cycloplegic refraction was performed. Uncorrected visual acuity (UCVA) was measured along with presenting vi... This study enrolled 724 828 schoolchildren (77.8% of all schoolchildren in Shantou) from 901 schools. Data from 721 032 schoolchildren (99.5%) were analysed (mean age 11.53±3.13 years, 6-20 years, 373... The overall prevalence of myopia among schoolchildren in Shantou was 51.8%, higher than the national average in China. The proportion of uncorrected myopia is high, especially in primary schools. Our ...

EVO/EVO+ Visian Implantable Collamer Lenses for the correction of myopia and myopia with astigmatism.

Intraocular lens implantation in phakic eyes for the correction of refractive error is currently a widespread procedure. The EVO and EVO+ Visian Implantable Collamer Lenses (ICL) are two of the most p... During the last decade, more than 100 scientific papers analyzing the performance of EVO and EVO+ lenses have been published. This review describes the objective visual performance achieved with the i... Refractive surgeons and candidates to undergo ICL implantation should be aware of the excellent safety and visual outcomes provided by the implantation of central hole ICL lenses. However, future rese...

Multiple segment spectacle lenses for myopia control. Part 2: Impact on myopia progression.

Initial studies have suggested that multiple segment (MS) spectacle lenses can reduce the progression rate of childhood myopia and axial eye growth. This paper aimed to compare the effectiveness of tw... Published data from the only two clinical trials in which changes in mean spherical equivalent refraction (SER) and axial length (AL) for matched groups of myopic children wearing either MS or single-... Absolute changes in SER and AL differed over time during the two trials. However, if the results were expressed in terms of efficacy over successive 6-month periods, then the two MS lenses produced br... Myopia control may be due to either the additional myopic defocus induced by the MS lenses (i.e., asymmetry of the through-focus image changes about the distance focus) or to the general reduction in ... Multiple segment spectacle lenses offer a valuable new approach to the control of myopia progression in children. Further work is required to clarify their mechanism of action and to optimise their de...

Retrospective Comparison of the Myopia Master and the Lenstar LS900 Axial Length Measurements in Children with Myopia.

This study is a retrospective analysis to compare ocular biometry measurements of axial length in children with myopia using Myopia Master (OCULUS, Wetzlar, Germany) and Lenstar LS900 (HAAG-STREIT AG,... Axial length measurements obtained with both instruments within a 3-week period were collected retrospectively. Measurements were visualized with a Bland-Altman plot. For statistical evaluation, a pai... Sixty-one eyes from 31 myopic patients (59% male, 41% female) with a mean age of 11.34 ± 3.25 years (range: 6 - 18 years) were identified. Mean axial length was 24.7 mm (SD 1.29) with the Myopia Maste... The axial length measured by Myopia Master and Lenstar LS900 did not differ significantly. Thus, previous values obtained with the Lenstar LS900 can be applied to assess myopia progression....

Myopia Control Dose Delivered to Treated Eyes by a Dual-focus Myopia-control Contact Lens.

This study examined the optical impact of a DF contact lens during near viewing in a sample of habitual DF lens wearing children.... Seventeen myopic children aged 14 to 18 years who had completed 3 or 6 years of treatment with a DF contact lens (MiSight 1 Day; CooperVision, Inc., San Ramon, CA) were recruited and fit bilaterally w... During near viewing, children wearing single-vision lenses accommodated on average to achieve approximate focus in the pupil center but, because of combined accommodative lag and negative spherical ab... The DF contact lens did not alter the accommodative behavior of children. The treatment optics introduced myopic defocus and decreased the amount of hyperopically defocused light in the retinal image....